What is the recommended treatment for uncomplicated cystitis in an otherwise healthy, non‑pregnant adult woman?

Recommended Treatment for Uncomplicated Cystitis in Non-Pregnant Adult Women

Nitrofurantoin 100 mg orally twice daily for 5 days is the preferred first-line therapy for uncomplicated cystitis in otherwise healthy, non-pregnant adult women, achieving approximately 93% clinical cure and 88% microbiological eradication with worldwide resistance rates below 1%. 1

First-Line Treatment Options

Nitrofurantoin (Preferred Agent)

• Nitrofurantoin monohydrate/macrocrystals 100 mg orally twice daily for 5 days provides superior efficacy compared to beta-lactams while causing minimal disruption to intestinal flora, thereby reducing the risk of Clostridioides difficile infection. 1
• This agent maintains excellent activity against E. coli, which causes 75–95% of uncomplicated cystitis cases. 1, 2
• Contraindication: Do not use when estimated glomerular filtration rate (eGFR) is <30 mL/min/1.73 m² because adequate urinary concentrations cannot be achieved. 2

Trimethoprim-Sulfamethoxazole (TMP-SMX)

• TMP-SMX 160/800 mg orally twice daily for 3 days achieves 93% clinical cure and 94% microbiological eradication when the pathogen is susceptible. 1, 3
• Critical prescribing criteria: Use TMP-SMX only when both of the following conditions are met:
  • Local E. coli resistance is documented to be <20% 1, 3
  • The patient has not received TMP-SMX in the preceding 3 months 1, 3
• When resistance exceeds 20%, clinical cure rates plummet to 41–54%, making treatment failure the expected outcome. 1, 3
• Many regions now exceed the 20% resistance threshold, rendering empiric TMP-SMX inappropriate without local antibiogram verification. 1, 2

Fosfomycin (Single-Dose Alternative)

• Fosfomycin trometamol 3 g as a single oral dose provides approximately 91% clinical cure with therapeutic urinary concentrations maintained for 24–48 hours. 1, 2
• This single-dose regimen offers superior adherence compared to multi-day courses while maintaining low resistance rates (2.6% in initial infections). 2
• Critical limitation: Fosfomycin should not be used for suspected pyelonephritis or upper-tract infections due to insufficient tissue penetration. 2

Treatment Selection Algorithm

Step 1: Assess local E. coli TMP-SMX resistance rates

• If resistance is <20% AND the patient has no TMP-SMX exposure in the past 3 months → prescribe TMP-SMX 160/800 mg twice daily for 3 days 1, 3
• If resistance is ≥20% OR local data are unavailable → proceed to Step 2 1, 2

Step 2: Select between nitrofurantoin and fosfomycin

• Preferred: Nitrofurantoin 100 mg twice daily for 5 days (provided eGFR ≥30 mL/min/1.73 m²) 1, 2
• Alternative: Fosfomycin 3 g single dose (for convenience or when nitrofurantoin is contraindicated) 1, 2

Step 3: Reserve agents (use only when first-line options fail or are contraindicated)

• Fluoroquinolones (ciprofloxacin 250 mg twice daily for 3 days) should be reserved for culture-proven resistant organisms only 1
• Beta-lactams (amoxicillin-clavulanate, cefdinir, cefpodoxime for 3–7 days) achieve only 89% clinical cure and 82% microbiological eradication, significantly inferior to first-line agents 1

Diagnostic Recommendations

When Urine Culture Is NOT Required

• Routine urine culture is unnecessary for otherwise healthy women presenting with typical lower-tract symptoms (dysuria, frequency, urgency) without systemic signs. 1, 2

When Urine Culture IS Mandatory

Obtain culture and susceptibility testing when any of the following occur:

• Persistent symptoms after completing the prescribed regimen 1, 2
• Recurrence of symptoms within 2–4 weeks 1, 2
• Fever >38°C, flank pain, or costovertebral angle tenderness suggesting pyelonephritis 1, 2
• Atypical presentation or presence of vaginal discharge 1, 2
• History of recurrent infections or prior resistant organisms 2

Management of Treatment Failure

• If symptoms persist after 2–3 days or recur within 2 weeks, obtain a urine culture immediately and switch to a different antibiotic class for a full 7-day course (not the original short regimen). 1, 2
• Assume the original pathogen is resistant to the previously used agent when retreating. 2
• Reserve fluoroquinolones only for culture-proven resistance to all first-line agents. 1

Critical Pitfalls to Avoid

• Do not use empiric fluoroquinolones as first-line therapy for uncomplicated cystitis; the FDA advisory (July 2016) warns that serious adverse effects (tendon rupture, peripheral neuropathy, CNS toxicity) outweigh benefits. 2
• Do not prescribe TMP-SMX without confirming local resistance is <20%; failure rates increase sharply above this threshold. 1, 3
• Do not treat asymptomatic bacteriuria in non-pregnant, non-catheterized women, as this promotes resistance without clinical benefit. 1, 2
• Do not use amoxicillin or ampicillin alone for uncomplicated cystitis; worldwide E. coli resistance exceeds 55–67%. 1
• Do not use nitrofurantoin for suspected pyelonephritis or when eGFR <30 mL/min/1.73 m². 1, 2
• Do not use oral fosfomycin for suspected upper-tract infection or pyelonephritis. 2

Post-Treatment Management

• Routine post-treatment urine cultures are unnecessary for asymptomatic patients who have completed therapy successfully. 2
• Symptom resolution alone is sufficient evidence of clinical cure; microbiologic reassessment in asymptomatic patients provides no additional benefit and may promote antimicrobial resistance. 2